NASDAQ:IBB iShares Nasdaq Biotechnology ETF Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding iShares Nasdaq Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $135.63 -0.53 (-0.39 %) (As of 09/17/2020 12:00 AM ET) Add Compare Share Today's Range$133.91Now: $135.63▼$136.3350-Day Range$126.88MA: $133.22▼$138.5752-Week Range$92.15Now: $135.63▼$146.53Volume2.66 million shsAverage Volume3.49 million shsMarket Capitalization$9.15 billionP/E RatioN/ADividend Yield0.23%Beta1.1 ProfileChartDividendFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Read More Geographic Exposure of IBBCurrency Exposure of IBBSector Exposure of IBBIndustry Exposure of IBB Basic Details Issuer BlackRock Fund NameiShares Nasdaq Biotechnology ETF Tax ClassificationRegulated Investment Company SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/A Fund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Fund Statistics Assets Under Management$7.70 billion Average Daily Volume$2.62 million Discount/Premium0.08% ETF Expenses Management Fee0.47% Other Expenses0.00% Total Expenses0.47% Fee Waiver0.00% Net Expenses0.47%Administrator, Advisor and Custodian AdministratorState Street Bank and Trust Company AdvisorBlackRock Fund Advisors CustodianState Street Bank and Trust Company DistributorBlackRock Investments, LLC Transfer AgentState Street Bank and Trust Company Trustee Lead Market MakerVirtu Financial $135.63 -0.53 (-0.39 %) (As of 09/17/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IBB News and Ratings via Email Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter. iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Frequently Asked Questions How has iShares Nasdaq Biotechnology ETF's stock been impacted by Coronavirus (COVID-19)? iShares Nasdaq Biotechnology ETF's stock was trading at $106.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IBB stock has increased by 26.8% and is now trading at $135.63. View which stocks have been most impacted by COVID-19. How often does iShares Nasdaq Biotechnology ETF pay dividends? What is the dividend yield for iShares Nasdaq Biotechnology ETF? iShares Nasdaq Biotechnology ETF declared a quarterly dividend on Wednesday, March 25th. Investors of record on Thursday, March 26th will be paid a dividend of $0.0554 per share on Tuesday, March 31st. This represents a $0.22 annualized dividend and a yield of 0.16%. The ex-dividend date is Wednesday, March 25th. View iShares Nasdaq Biotechnology ETF's dividend history. When did iShares Nasdaq Biotechnology ETF's stock split? How did iShares Nasdaq Biotechnology ETF's stock split work? iShares Nasdaq Biotechnology ETF shares split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split. Who are some of iShares Nasdaq Biotechnology ETF's key competitors? Some companies that are related to iShares Nasdaq Biotechnology ETF include DNP Select Income Fund (DNP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), PIMCO Corporate&Income Opportunity Fund (PTY), Tri-Continental (TY), Gabelli Equity Trust (GAB), Hercules Capital (HTGC), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Boulder Growth & Income Fund (BIF), AllianceBernstein Global Hgh Incm Fd (AWF), SPDR Bloomberg Barclays International Treasury Bond ETF (BWX), Blackrock Muniyield Insured Fund (MYI), Tekla Healthcare Investors (HQH) and Tortoise Energy Infrastructure (TYG). View all competitors. What other stocks do shareholders of iShares Nasdaq Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Nasdaq Biotechnology ETF investors own include NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and Paypal (PYPL). Who are iShares Nasdaq Biotechnology ETF's key executives? iShares Nasdaq Biotechnology ETF's management team includes the following people: George G. C. Parker Ph.D., Independent Chairman of the Board of TrusteesMichael Arthur Latham, President, TrusteeJack Gee, Chief Financial Officer, TreasurerGeoffrey D. Flynn, Chief Operating Officer, Executive Vice President, Bio & Compensation - Amy Schioldager, Executive Vice PresidentIra P. Shapiro, Vice President, Chief Legal OfficerMatt Tucker, Vice President, Bio & Compensation - Eilleen M. Clavere, SecretaryCecilia H. Herbert, Independent TrusteeCharles A. Hurty, Independent Trustee What is iShares Nasdaq Biotechnology ETF's stock symbol? iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB." Who are iShares Nasdaq Biotechnology ETF's major shareholders? iShares Nasdaq Biotechnology ETF's stock is owned by a variety of retail and institutional investors. Top institutional investors include CHURCHILL MANAGEMENT Corp (2.24%), PNC Financial Services Group Inc. (0.94%), Envestnet Asset Management Inc. (0.60%), QVT Financial LP (0.44%), Total Investment Management Inc. (0.42%) and First Republic Investment Management Inc. (0.38%). Which institutional investors are selling iShares Nasdaq Biotechnology ETF stock? IBB stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Estate Counselors LLC, Sawtooth Solutions LLC, AE Wealth Management LLC, Janney Capital Management LLC, Glenmede Trust Co. NA, Bank of Nova Scotia, and Simplex Trading LLC. Which institutional investors are buying iShares Nasdaq Biotechnology ETF stock? IBB stock was bought by a variety of institutional investors in the last quarter, including CHURCHILL MANAGEMENT Corp, Envestnet Asset Management Inc., Total Investment Management Inc., Stadion Money Management LLC, Advisors Preferred LLC, DAVENPORT & Co LLC, SG Americas Securities LLC, and QVT Financial LP. How do I buy shares of iShares Nasdaq Biotechnology ETF? Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is iShares Nasdaq Biotechnology ETF's stock price today? One share of IBB stock can currently be purchased for approximately $135.63. How big of a company is iShares Nasdaq Biotechnology ETF? iShares Nasdaq Biotechnology ETF has a market capitalization of $9.15 billion. This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
